PRAME (Preferentially Expressed Antigen of Melanoma, Melanoma Antigen Preferentially Expressed in Tumors, MAPE, CT130, OPA Interacting Protein 4, OPA-interacting Protein 4, Opa-interacting Protein OIP4, OIP4)

• Catalog number
  MBS641754
• Price
  Please ask
• Size
  5x0.05 mg

• Products_type
  Antibody
• Products_short_name
  [PRAME]
• Products_name_syn
  [Anti -PRAME (Preferentially Expressed Antigen of Melanoma, Melanoma Antigen Preferentially Expressed in Tumors, MAPE, CT130, OPA Interacting Protein 4, OPA-interacting Protein 4, Opa-interacting Protein OIP4, OIP4)]
• Other_names
  [PRAME; Melanoma antigen preferentially expressed in tumors; Opa-interacting protein 4; OIP-4; Preferentially expressed antigen of melanoma]
• Other_gene_names
  [PRAME; MAPE; OIP4; OIP-4]
• Clonality
  Polyclonal
• Reactivity
  Human
• Specificity
  Recognizes human PRAME.
• Purity
  Affinity Purified Purified by Protein A affinity chromatography.
• Form
  Supplied as a liquid in PBS, pH 7.2.
• Storage_stability
  May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Tested_application
  Western Blot (WB)
• Description
  Antigens are peptides or recombinant or native dependent on the production method.

• Gene target
  PRAME   Preferentially   Expressed   Melanoma   Melanoma   Preferentially   Expressed   Tumors   MAPE   CT130   OPA   Interacting   Protein   OPA-interacting   Protein   Opa-interacting   Protein   OIP4   OIP4  
• Gene symbol
  PRAME
• Short name
  PRAME (Preferentially Expressed Antigen of Melanoma, Melanoma Antigen Preferentially Expressed in Tumors, MAPE, CT130, OPA Interacting Protein 4, OPA-interacting Protein 4, Opa-interacting Protein OIP4, OIP4)
• Technique
  antigen, antigenes
• Host
  Mouse
• Isotype
  IgG
• Alternative name
  preferentially expressed antigen in melanoma (Preferentially Expressed protein on Melanoma, Melanoma protein Preferentially Expressed in Tumors, MAPE, CT130, OPA Interacting Protein 4, OPA-interacting Protein 4, Opa-interacting Protein OIP4, OIP4)
• Alternative technique
  antigenes
• Alternative to gene target
  preferentially expressed antigen in melanoma, CT130 and MAPE and OIP-4 and OIP4, PRAME and IDBG-2240 and ENSG00000185686 and 23532, retinoic acid receptor binding, nuclei

Gene info

• Identity
  HGNC:9336
• Gene
  PRAME
• Long gene name
  PRAME nuclear receptor transcriptional regulator
• Synonyms gene
  • MAPE
• Synonyms gene name
  • preferentially expressed antigen in melanoma
• Synonyms
  • CT130
• Synonyms name
  • cancer/testis antigen 130
• GenBank acession
  • U65011
• Locus
  22q11.22
• Discovery year
  1996-06-21
• Entrez gene record
  23532
• Pubmed identfication
  • 9047241
  • 10591208
• RefSeq identity
  • NM_206953
• Classification
  • PRAME family
• VEGA ID
  OTTHUMG00000151172

MeSH Data

• Name
  Tumor Stem Cell Assay
• Concept
  Scope note: A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
• Tree numbers
  • E01.370.225.500.383.910
  • E01.370.225.500.388.930
  • E05.200.500.383.910
  • E05.200.500.388.930
  • E05.242.383.910
  • E05.242.417.500
  • E05.337.550.200.800
• Qualifiers
  ethics, trends, veterinary, history, classification, economics, instrumentation, methods, standards, statistics & numerical data

Similar products